5 Key Takeaways

• 1

  Matt Nelson, founder of SentryDx, aims to improve liquid biopsy diagnostics using his innovative Bicycle PCR technology.

• 2

  Nelson's background in bacterial genetics and gene editing led him to develop a more accurate method for detecting cancer DNA.

• 3

  Bicycle PCR addresses limitations of traditional blocking PCR by allowing normal DNA levels to be detected alongside cancer DNA.

• 4

  Independent validation confirmed that Bicycle PCR can detect cancer DNA at a sensitivity of 0.02 percent, surpassing existing FDA-approved tests.

• 5

  Nelson's motivation to improve cancer diagnostics stemmed from personal experiences with a family member's battle with breast cancer.